Beauty Health (NASDAQ:SKIN) Stock Rating Reaffirmed by Benchmark

Beauty Health (NASDAQ:SKIN – Get Rating)‘s stock had its “buy” rating restated by stock analysts at Benchmark in a research note issued on Tuesday, Benzinga reports. They currently have a $23.00 price objective on the stock. Benchmark’s price target suggests a potential upside of 95.08% from the company’s previous close.

Several other equities research analysts also recently issued reports on the company. DA Davidson upped their price target on Beauty Health from $32.00 to $35.00 and gave the stock a “buy” rating in a report on Wednesday, March 1st. Cowen decreased their price target on Beauty Health from $20.00 to $15.00 and set an “outperform” rating for the company in a report on Thursday, February 16th. The Goldman Sachs Group decreased their price target on Beauty Health from $22.00 to $19.00 and set a “buy” rating for the company in a report on Wednesday, November 23rd. Finally, Piper Sandler cut their price objective on Beauty Health from $16.00 to $15.00 in a research report on Friday, December 16th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, Beauty Health presently has a consensus rating of “Moderate Buy” and an average target price of $19.75.

Beauty Health Trading Up 2.4 %

NASDAQ SKIN opened at $11.79 on Tuesday. The business has a 50 day moving average price of $11.56 and a 200-day moving average price of $11.17. Beauty Health has a 52 week low of $8.25 and a 52 week high of $19.38. The company has a market cap of $1.56 billion, a price-to-earnings ratio of -65.50 and a beta of 1.16. The company has a quick ratio of 9.20, a current ratio of 10.79 and a debt-to-equity ratio of 4.28.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in SKIN. Nisa Investment Advisors LLC lifted its position in shares of Beauty Health by 88.9% during the 3rd quarter. Nisa Investment Advisors LLC now owns 4,490 shares of the company’s stock valued at $52,000 after buying an additional 2,113 shares during the last quarter. State of Wyoming lifted its position in shares of Beauty Health by 46.4% during the 4th quarter. State of Wyoming now owns 6,791 shares of the company’s stock valued at $62,000 after buying an additional 2,152 shares during the last quarter. Point72 Hong Kong Ltd purchased a new position in shares of Beauty Health during the 3rd quarter valued at $85,000. Royal Bank of Canada lifted its position in shares of Beauty Health by 22.8% during the 3rd quarter. Royal Bank of Canada now owns 7,700 shares of the company’s stock valued at $91,000 after buying an additional 1,430 shares during the last quarter. Finally, Amundi purchased a new stake in Beauty Health during the 2nd quarter worth about $92,000. Hedge funds and other institutional investors own 78.37% of the company’s stock.

Beauty Health Company Profile

(Get Rating)

The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, peel, exfoliate, extract, infuse, and hydrate the skin with proprietary solutions and serums.